No predictors of antidepressant patient response to milnacipran were obtained using the three‐factor structures of the Montgomery and Åsberg Depression Rating Scale in Japanese patients with major depressive disorders

Aims:  Milnacipran, a new specific serotonin and norepinephrine re‐uptake inhibitor, is as effective as tricyclic antidepressants. Symptomatological predictors of antidepressant response to milnacipran have not been studied until now.

[1]  Y. Sugawara,et al.  Response Rate Obtained Using Milnacipran Depending on the Severity of Depression in the Treatment of Major Depressive Patients , 2006, Clinical neuropharmacology.

[2]  S. Morishita,et al.  Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression , 2004, European Psychiatry.

[3]  S. Morishita,et al.  Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age , 2004, Human psychopharmacology.

[4]  Hubertus Himmerich,et al.  Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). , 2003, Journal of affective disorders.

[5]  Y. Hishikawa,et al.  Milnacipran plasma levels and antidepressant response in Japanese major depressive patients , 2003, Human psychopharmacology.

[6]  D. Steffens,et al.  A three‐factor analytic model of the MADRS in geriatric depression , 2003, International journal of geriatric psychiatry.

[7]  R. Tsujita,et al.  Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats , 2002, Psychopharmacology.

[8]  K. Kanemoto,et al.  Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case–control study , 2002, International clinical psychopharmacology.

[9]  M. Hammond.  Rating depression severity in the elderly physically ill patient: reliability and factor structure of the Hamilton and the Montgomery–Asberg Depression Rating Scales , 1998, International journal of geriatric psychiatry.

[10]  S. Kasper,et al.  Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results , 1996, International clinical psychopharmacology.

[11]  E. Richelson.  Synaptic Effects of Antidepressants , 1996, Journal of clinical psychopharmacology.

[12]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[13]  K. Otani,et al.  A three‐factor model of the MADRS in major depressive disorder , 2005, Depression and anxiety.

[14]  D. Evans,et al.  Factor analysis of the Montgomery-Asberg Depression Rating Scale. , 1996, Depression.